EPO revokes two more DNA-sequencing patents despite Illumina appeal.
The EPO Boards of Appeal have confirmed the revocation of two more Illumina patents concerning DNA-sequencing technology. The same boards also issued a negative preliminary opinion concerning a third patent held by the US manufacturer of genetic engineering equipment.
CH KILGER WAS IN ATTENDANCE OF THE CONFERENCE ON SUSTAINABLE AVIATION FUEL HELD FOR GOVERNMENT OFFICIALS IN DUBAI (UAE) IN NOVEMBER 2023.
The International Civil Aviation Organization was the host of this politically important event for the entire aviation industry.
INNOVATORS AND GOVERNMENTS MEET IN DUBAI FOR SUSTAINABLE AVIATION FUELS – ICAO 3
Well over a hundred countries and one thousand delegates are convening in Dubai this week to firm up their collective commitments to boost global aviation’s transition towards Sustainable Aviation Fuels (SAF), Lower Carbon Aviation Fuels (LCAF), and other cleaner energy sources. Read more
Webinar:
STRAIN BANKING: HOW TO TRANSFORM SAMPLES INTO ASSETS
25 January 2023 / 90 Minutes
Sponsored by Biomillenia
CH KILGER PREVAILS IN PATENT INFRINGEMENT PROCEEDINGS BEFORE THE HIGHER REGIONAL COURT OF MUNICH I
CH KILGER ASSISTS DIDAC COSTA IN VENDÉE GLOBE RACE
Innovation is needed for the world to solve the plastic problem
3 in ONE STRIKE – ILLUMINA PATENTS INVALIDATED BY CH KILGER
The European Patent Office has destroyed several patents belonging to Illumina, a US manufacturer of DNA sequencing machine and a market leader in the field.
Engineering in Medicine an Biology (EMBC) Conference Invites Dr. Christian Kilger
Dr. Colin Brenan, CEO 1CellBio and a famous serial entrepreneur from Boston, USA invited Patent Attorney Dr. Christian Kilger to talk at the EMBC conference in Berlin at the City Cube. Read more
Partial victory for AbbVie in biosimilar dispute
Rheumatism drug Humira is one of pharmaceutical company AbbVie’s most valuable biosimilars. In ongoing disputes over the patent family, the European Patent Office Opposition Division finally rejected all oppositions in the oral hearing concerning the divisional application EP 2940 044. A significant aspect of the decision is the argument regarding priority.
